Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Sep 8;4(1):21-31.
doi: 10.1002/mdc3.12425. eCollection 2017 Jan-Feb.

The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues

Matej Skorvanek  1   2 , Kailash P Bhatia  3
Affiliations
Review

The Skin and Parkinson's Disease: Review of Clinical, Diagnostic, and Therapeutic Issues

Matej Skorvanek et al. Mov Disord Clin Pract. .

Abstract

Background: Parkinson's disease (PD) and the skin are related in a number of ways, including clinical abnormalities of the disease itself and skin-related side effects of dopaminergic medication, pumps, and surgical therapies. Recent advances in understanding the role of α-synuclein suggest skin biopsies as a potential diagnostic or even a premotor marker of PD.

Methods: The PubMed database was searched for publications up to October 2015, and the current evidence on skin-related issues in PD was comprehensively summarized.

Results: The evidence was summarized on the prevalence, etiology, and management of seborrheic dermatitis, sweating dysfunctions, bullous pemphigoid, and malignant melanoma, as well as therapy-related skin disorders, especially those observed in amantadine, rotigotine, apomorphine, and levodopa/carbidopa intestinal gel therapies and deep-brain stimulation. Skin biopsies evaluating the presence of α-synuclein, the density and morphology of cutaneous nerves, and skin fibroblast functions also are discussed.

Conclusions: Skin disorders are a common manifestation of PD. However, the exact pathophysiology and prevalence of these disorders are not well understood, and more systematic research is needed in this regard. Peripheral tissue biopsies as a diagnostic marker of PD are an exciting avenue in future PD research, although multiple caveats and pending issues need to be solved before they can be used in routine clinical practice.

Keywords: Parkinson's disease; melanoma; skin; therapy; α‐synuclein.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Bullous pemphigoid (courtesy of Dr. Zuzana Hrabovska, Department of Dermatology, University Hospital of L. Pasteur, Kosice, Slovakia).
Figure 2
Figure 2
Subcutaneous nodules associated with apomorphine pump therapy.
Figure 3
Figure 3
Local infection and subcutaneous abscess associated with percutaneous endoscopic gastrostomy stoma.
Figure 4
Figure 4
Skin infection and wound dehiscence over a deep‐brain stimulation implantable pulse generator.
See this image and copyright information in PMC

References

    1. Krestin D. The seborrheic facies as a manifestation of post‐encephalitic parkinsonism and allied disorders. Q J Med 1927;21:177–186.
    1. Pont‐Sunyer C, Hotter A, Gaig C, et al. The onset of nonmotor symptoms in Parkinson's disease (the ONSET PD study). Mov Disord 2015;30:229–237. - PubMed
    1. Chen YJ, Wu CY, Lin MW, et al. Comorbidity profiles among patients with bullous pemphigoid a nationwide population‐based study. Br J Dermatol 2011;165:593–599. - PubMed
    1. Huang P, Yang XD, Chen SD, et al. The association between Parkinson's disease and melanoma: a systematic review and meta‐analysis [serial online]. Transl Neurodegener 2015;4:21. - PMC - PubMed
    1. Fedorow H, Tribl F, Halliday G, Gerlach M, Reiderer P, Double KL. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol 2005;75:109–124. - PubMed